Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Capital Investment Counsel Inc

Capital Investment Counsel Inc decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,125 shares of the medical research company’s stock after selling 300 shares during the quarter. Capital Investment Counsel Inc’s holdings in Edwards Lifesciences were worth $379,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Concurrent Investment Advisors LLC grew its stake in shares of Edwards Lifesciences by 2.3% in the fourth quarter. Concurrent Investment Advisors LLC now owns 19,626 shares of the medical research company’s stock valued at $1,453,000 after buying an additional 439 shares in the last quarter. Abacus Planning Group Inc. grew its stake in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of Edwards Lifesciences by 79.4% in the fourth quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock valued at $1,579,000 after buying an additional 9,440 shares in the last quarter. Pegasus Asset Management Inc. grew its stake in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after buying an additional 159 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in Edwards Lifesciences by 1,013.3% in the fourth quarter. Venturi Wealth Management LLC now owns 2,683 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 2,442 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent research reports. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $74.71 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average price is $72.86 and its 200 day moving average price is $69.86. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $44.06 billion, a PE ratio of 10.72, a price-to-earnings-growth ratio of 4.89 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.